Abstract Purpose: To assess the effects of external beam radiotherapy (EBRT) on adenoviral-mediated transgene expression in vitro and in vivo and to define an optimal strategy for combining sodium iodide symporter (NIS)^mediated 131 I therapy with EBRT. Experimental Design: Expression of reporter genes [NIS, green fluorescent protein (GFP), h-galactosidase (lacZ), and luciferase (Luc)] from replication-deficient adenoviruses was assessed in tumor cell lines under basal conditions and following irradiation. The effects of viral multiplicity of infection (MOI) and EBRTdose on the magnitude and duration of gene expression were determined. In vivo studies were done with Ad-CMV-GFP and Ad-RSV-Luc. Results: EBRT increased NIS, GFP, and h-galactosidase expression in colorectal, head and neck, and lung cancer cells. Radiation dose and MOI were important determinants of response to EBRT, with greatest effects at higher EBRTdoses and lower MOIs. Radiation exerted both transductional (through increased coxsackie-adenoviral receptor and integrin a v ) and nontransductional effects, irrespective of promoter sequence (CMV, RSV, hTR, or hTERT). Analysis of the schedule of EBRT followed by viral infection revealed maximal transduction at 24 hours. Radiation maintained increasing radioiodide uptake from Ad-hTR-NIS over 6 days, in direct contrast to reducing levels in unirradiated cells. The effects of EBRT in increasing and maintaining adenovirus-mediated transgene expression were also seen in vivo using GFP-and luciferase-expressing adenoviral vectors. Conclusions: Radiation increased the magnitude and duration of NIS gene expression from replication-deficient adenoviruses. The transductional effect is maximal at 24 hours, but radioiodide uptake is maintained at an elevated level over 6 days after infection.
The sodium iodide symporter (NIS) belongs to the sodium/ solute symporter family, comprising more than 60 membrane transport proteins with structural and functional homology. The human NIS gene encodes a 643-amino-acid intrinsic membrane glycoprotein with 13 putative transmembrane domains, an extracellular NH 2 terminus, and an intracellular COOH terminus (1) . NIS mediates Na + /K + ATPase -dependent active transport of iodide across the basolateral membrane of thyroid follicular cells. Iodide is subsequently transported into the follicular lumen and undergoes thyroperoxidase-mediated organification. This reaction is not observed in NIS-expressing extrathyroidal tissues, such as salivary glands, gastric mucosa, and lactating mammary gland (reviewed in ref. 2) . NIS expression correlates with iodide uptake and radioiodide responsiveness in papillary thyroid tumors (3) . Metastatic thyroid cancer can be cured by radioiodide treatment. The aim of NIS gene therapy is to make nonthyroid cancers behave like thyroid cancer.
NIS-mediated genetic radionuclide therapy has undergone extensive preclinical evaluation (4 -10) . Adenoviral NIS gene delivery causes cell death on 131 I treatment in many tumor cell lines. Several investigators have confirmed the efficacy of in vivo NIS-mediated 131 I therapy in nonthyroid (glioma, prostate, and head and neck cancer) malignancies, allaying initial doubts that the lack of iodide organification in nonthyroid tissues would jeopardize therapeutic efficacy (4 -6, 8 -10) . In vivo NIS gene transfer has also been shown by noninvasive imaging of xenografts by g-camera scintigraphy after 125 I or 99m Tc injection, suggesting that NIS may serve both as a therapeutic and reporter gene in clinical trials (7) . NIS-mediated cytotoxicity results primarily from h-particulate radiation from 131 I accumulated in transduced cells (selfdose effect; ref. 11) . h-particles (range, 0.5-0.8 mm) also mediate a direct bystander effect by killing untransduced neighboring tumor cells (cross-fire effect; ref . 11) . The use of more densely ionizing radioisotopes with relatively short decay path lengths (e.g., 211 At) represents a way of optimizing the cross-fire effect in spheroid models (12, 13) . The activation of downstream signaling pathways in cells not directly in the h-particle track can also cause an indirect radiation-induced biological bystander effect (11, 14, 15) . This latter effect was elegantly demonstrated by showing that a DNA-bound Auger electron emitter ( 125 I) with a range of <0.5-Am-mediated cell death in adjacent unlabeled cells (14) .
There is increasing awareness that viral gene therapy may be clinically applicable as part of combined treatment with external beam radiotherapy (EBRT; ref. 16 Several studies have reported increased expression of transgenes from adenoviruses after exposure to EBRT or DNA-damaging drugs. Qian et al. (18) reported a 6.5-to 24.4-fold EBRT-induced increase in adenoviral uptake and gene expression in colon cancer cells in vitro and in vivo (18) . This correlated with EBRT-induced induction of dynamin-2. Increased expression from cytomegalovirus (CMV) -driven adenoviral constructs has been reported after exposure to DNA-damaging agents (cisplatin and N-acetoxy-acetylaminofluorine; ref. 19) .
In this article, we present detailed analyses of the effects of EBRT on the expression of transgenes from replication-defective adenoviral vectors. These studies provide important background information in support of future clinical development of therapeutic approaches using NIS gene delivery in combination with EBRT.
Materials and Methods
Cell lines. HCT 116 (colorectal cancer cell line), SIHN-5B and HN5 (both head and neck cancer cell lines), and H1299 (lung cancer cell line) cells were maintained at 37jC and 5% CO 2 in a humidified incubator in DMEM containing 5% (v/v) FCS, 1% (v/v) glutamine, and 0.5% (v/v) penicillin/streptomycin. Adenoviral vectors and infections. Stocks of replication-defective adenoviral vectors expressing green fluorescent protein (Ad-CMV-GFP), h-galactosidase (Ad-CMV-lacZ), firefly luciferase (Ad-RSV-Luc), and the NIS (Ad-CMV-NIS, Ad-hTR-NIS, and Ad-hTERT-NIS) were stored at -80jC. Infections were performed at 70% to 75% confluence (f1 Â 10 5 cells in 24-well plates/5Â 10 5 cells in 6-well plates) in DMEM supplemented with 2% FCS. Cells were subsequently incubated at 37jC for at least 4 h, followed by addition of fresh medium. Cells were subjected to functional analyses at fixed time points following infection as described for individual experimental conditions.
Antibodies. Primary antibodies to coxsackie adenoviral receptor (CAR; murine IgG1; Upstate Cell Signaling Solutions) and integrin a V receptor (rabbit IgG; Santa Cruz Biotechnologies) were obtained. Secondary FITC-conjugated donkey anti-mouse and recombinant phycoerythrin -conjugated goat anti-rabbit antibodies were obtained from Southern Biotech.
Cell irradiation. All irradiations were done using a Pantak H.F. 320 kV X-ray machine. Before irradiation of cells, the dose rate was determined using a Farmer Sub-Standard X-ray dosimeter Mk.2/S3 according to the manufacturer's instructions. The dose rate for irradiations was 6.6 to 6.8 Gy/min at 240 kVp and 10 mA. Cells were irradiated in 24-well (BD Labware) or 96-well (Nunc) plates or in 75-cm 2 tissue culture flasks (BD Biosciences), depending on the experimental design.
Iodide uptake assays. Cells were seeded in 24-well plates at 1 Â 10 5 per well and infected with NIS-expressing adenoviral vectors 16 h later. At predetermined time points after infection, cells were treated with 200 AL buffered HBSS containing Na
125
I with specific activity of 1 ACi/mL. Potassium perchlorate (KClO 4 ) at a concentration of 50 Amol/L was added to the control wells. Cells were incubated at 37jC for 60 min and then washed twice with ice-cold HBSS. Trapped iodide was removed from cells by a 20-min incubation in 1 mol/L NaOH, and radioactivity was measured in counts per minute by running the samples through a scintillation counter (Beckman Coulter). Counts per minute per cell was measured by simultaneous harvesting and counting of cells in a control tissue culture plate.
Fluorescence-activated cell sorting for GFP expression. Ad-CMV-GFP was used to infect 1 Â 10 6 cells in 75-cm 2 tissue culture flasks. At specific time points following infection, the cell monolayer was trypsinized, washed vigorously thrice with 4 mL PBS, and resuspended as a single-cell suspension at 1 Â 10 6 cells/mL. Propidium iodide was added to each sample at 1 Ag/mL. Samples were analyzed on a FACScan flow cytometer (Becton Dickinson).
Chlorophenol red b-D-galactopyranoside assay for LacZ expression. Research.
on January 6, 2018. © 2008 American Association for Cancer clincancerres.aacrjournals.org Downloaded from 10 mg/mL; Janssen-Cilag Ltd.), Hypnovel (midazolam, 5 mg/mL; Roche Products Ltd.), and water for injection BP (Fresenius Health Care Group). Anesthetized animals were positioned in an irradiation jig with the subcutaneous tumors exposed under an aperture in a 3-mm lead sheet, and a localized radiation dose (0 or 8 Gy for Ad-CMV-GFP experiments; 0 or 5 Gy for Ad-RSV-Luc experiments) was delivered to the tumor using the Pantak H.F. 320 kV X-ray machine.
For assessment of GFP expression, 1 Â 10 6 plaque-forming units of Ad-CMV-GFP were injected intratumorally 24 h postirradiation, and 96 h later, the mice were sacrificed and the tumors were dissected out. Tumors were disaggregated, filtered through a 35-Am nylon mesh (BD Biosciences), and washed to give a single-cell suspension. In vivo GFP expression was assessed by fluorescence-activated cell sorting analysis as described above.
For assessment of Luc expression, 1 Â 10 8 plaque-forming units of Ad-RSV-Luc were injected intratumorally 24 h postirradiation. Luc expression was quantitated by real-time bioluminescent imaging using the IVIS system 200 series (Xenogen Biosciences) at 24 h (baseline) and other time points (48, 120, and 192 h) postinfection. D-Luciferin Firefly Potassium salt (Xenogen Biosciences; 1 g in 66 mL PBS; 15 mg/mL) was given at 150 mg/kg and imaging was done after 5 min. One-minute continuous exposures were obtained at high sensitivity using the machine default settings (f/stop, 1; emission filter, open; field of view diameter, 12 cm; and subject height, 1.5 cm). The Xenogen software provides visual images of bioluminescence detection using a colored overlay on a photographic image taken immediately before luminescence measurements. The areas shown in color represent the regions of bioluminescence detection. Results were analyzed using Living image 2.60.1 software (Xenogen Biosciences). Areas of Luc expression were defined using the autocontouring tool and the photon flux, and average radiance (photons/cm 2 /s) was estimated over the defined area.
Statistics. Statistical analysis was done using SPSS software (SPSS, Inc.) package. In vitro data on NIS, lacZ, and Luc gene expression were tested for normality using Levene's test and analyzed by the independent samples two-tailed t test. For analysis of in vivo Luc expression, mean photon flux values were transformed logarithmically and statistical analyses were done using the independent samples t test. Relative gene expression in vivo was compared using the Mann-Whitney U test.
Results

Adenoviral vectors expressing NIS mediate iodide uptake.
Initial studies addressed adenovirus-mediated NIS delivery from different regulatory promoter sequences in cancer cell lines. Four tumor cell lines [HCT116 (colorectal), SIHN-5B, HN5 (both head and neck), and H1299 (lung)] were infected with adenoviral vectors expressing NIS regulated by the constitutive (CMV) or telomerase (hTR, hTERT) promoters, and NIS expression was quantitated by performing radioiodide uptake assays at various time points after infection. NIS expression from the hTR promoter was comparable with that from the constitutive CMV promoter, but the hTERT promoter was significantly weaker. Representative data are presented for HCT116 cells at 72 hours after infection (Fig. 1A) . Similar data were seen with the other cell lines (data not shown). NISmediated radioiodide uptake exhibited MOI dependency and was inhibited by addition of the competitive inhibitor perchlorate (data not shown). Thereafter, Ad-CMV-NIS expression was evaluated in HCT116 cells as a function of time after infection. NIS expression increased progressively for 72 hours after infection, and this was followed by a stabilization or decrease in the level of gene expression, especially at MOIs of 1 and 10 (Fig. 1B) . Based on these data, further experiments on NIS involved measuring radioiodide uptake between 48 and 144 hours after viral infection.
EBRT enhances transgene expression from adenoviral vectors. Tumor cells were irradiated (0, 4, and 8 Gy) and infected at Fig. 1 . A, radioiodide uptake assay using adenoviruses expressing NIS from constitutive (CMV) and telomerase (hTR, hTERT) promoters. HCT116 were infected with Ad-CMV-NIS, Ad-hTR-NIS, orAd-hTERT-NIS at MOIs 0.1, 1, and10. MOIdependent radioiodide uptake measured in counts per minute was seen at 72 h. Data are representative of at least three repeat experiments. B, time course of radioiodide uptake after infection with Ad-CMV-NIS at MOI 0.1,1, and10.There was negligible radioiodide uptake at 24 h postinfection followed by a rapid increase between 48 and 72 h. Data are representative of at least three repeat experiments. C, radiationinduced enhancement of transgene expression from Ad-CMV-NIS vector. HCT116 cells were irradiated (0, 4, or 8 Gy) and infected with Ad-CMV-NIS (MOI: 0.01, 0.1,1, 10) 24 h later. Radioiodide uptake assay was done at 72 h, and data were expressed as relative uptake using the 0 Gy data for reference (1.0). Relative iodide uptake was significantly increased at MOI 0.01after both 4 Gy (2.31 F0.21; P = 0.001) and 8 Gy (1.85 F 0.03; P = 0.001), and at MOI 0.1after both 4 Gy (2.18 F 0.34; P = 0.005) and 8 Gy (1.78 F 0.37; P = 0.027). Relative radioiodide uptake was reduced at various time points with different MOIs (0.01, 0.1, 1, and 10 ) of the relevant adenoviral vector expressing NIS or another reporter gene (GFP, lacZ). Experiments were done using vectors under CMV or telomerase promoters (hTR, hTERT). Radioiodide uptake assay, flow cytometry, h-D-galactopyranoside, or Luc assays were done to quantitate the levels of NIS, GFP, lacZ, or Luc expression, respectively. The effect of radiation on gene expression from a constitutive viral (CMV or RSV) promoter was initially assessed. Radiation was associated with a 2.5-fold increase in the level of NIS (Fig. 1C) , a 2-to 4-fold increase in the level of GFP ( Fig. 2A and B) and lacZ (Fig. 2C) Supplementary Fig. S1 . Radiation-induced upregulation of Luc expression was 2-to 3-fold (data not shown) and 6-to 20-fold when adjusted to take radiation-induced cell death into account (Supplementary Fig. S2 ).
Radiation-induced up-regulation of NIS expression was radiation dose dependent and more pronounced at lower MOIs (Fig. 1C) . Indeed, at higher MOIs, there was no increase (MOI, 1) or decrease (MOI, 10) in radioiodide uptake after irradiation. Similar effects were also observed in other cell lines (SIHN-5B, H1299; data not shown).
Thereafter, further experiments were done in HCT116 and SIHN-5B cells with NIS-expressing vectors under transcriptional control of the hTR and hTERT promoters. Once again, irradiation up-regulated (up to 2.5-fold) NIS expression in a radiation dose-dependent manner that was most marked at low MOIs for Ad-hTR-NIS (Fig. 3A) and at higher MOIs for AdhTERT-NIS (Fig. 3B) .
Time course of radiation-induced up-regulation of adenoviral gene expression. Having confirmed that radiation up-regulates transgene expression from adenoviral vectors, the effect of varying the interval between radiation and viral infection was examined. Keeping the same basic methodology, HCT116 cells were infected with Ad-CMV-GFP at various time points (0, 24, and 48 hours) postirradiation and the level of GFP expression at 72 hours postinfection was determined. The greatest up-regulation of GFP expression was observed when infection was done at 24 hours after radiation (Fig. 3C and D) .
We then examined the effect of tumor cell irradiation on the time course of transgene expression from an adenoviral vector. In these experiments, cells were infected with different MOIs of Ad-hTR-NIS 24 hours after irradiation and serial estimations of transgene expression were done at regular intervals up to 6 days after infection. The level of gene expression increased with time in the irradiated cell lines, with higher levels of expression observed at later time points in the cells infected with the lower MOIs (0.01 and 0.1) of Ad-hTR-NIS. At these lower MOIs, radioiodide uptake was at its greatest level at 144 hours in cells irradiated to 8 Gy and this contrasted sharply with the decreasing levels of gene expression in unirradiated cells at this time (Fig. 4A and B) .
Irradiation up-regulates expression of adenoviral receptors. The effect of radiation on adenoviral receptor expression (CAR and integrin a v ) was investigated. Cells were irradiated and prepared for fluorescence-activated cell sorting analysis of receptor expression using appropriate primary and fluorescent secondary antibodies at various time points after irradiation (4, 24, and 48 hours). Radiation up-regulated CAR expression at 24 and 48 hours in both SIHN-5B and HCT116 cell lines. Similarly, integrin expression was up-regulated at 24 and 48 hours and, in the case of SIHN-5B cells, also at 4 hours ( Supplementary Fig. S3A and B) . These data provide a potential explanation for the up-regulation of gene expression through enhanced viral transduction of irradiated cells. Data are representative of at least three repeat experiments. C, radiation-induced enhancement of transgene expression from Ad-CMV-lacZ vector. HCT116 cells were infected with Ad-CMV-lacZ and irradiated (0, 1, or 3 Gy) 24 h later. LacZ expression was measured at 24, 48, and 120 h postirradiation using the chlorophenol red h-D-galactopyranoside assay. LacZ expression was significantly increased at 48 h after 3 Gy irradiation (0 Gy, 0.10 F 0.14 pg/AL; 3 Gy, 1.58 F 0.38 pg/AL; P < 0.001) and at 120 h after both 1and 3 Gy irradiation (0 Gy, 1.36 F 0.45 pg/AL; 1Gy, 3.59 F 0.92 pg/AL; P = 0.005; 3 Gy, 6.11 F1.47 pg/AL; P = 0.001). Data are representative of at least three repeat experiments. Further data from experiments using 4 and 8 Gy are presented in Supplementary Fig. S1 .
Schedule dependence of radiation-induced up-regulation of adenoviral gene expression. To examine whether mechanisms other than increased viral transduction play a role in upregulation of transgene expression, experiments were done in which the previous order of irradiation followed by infection was reversed, such that cells were infected with different MOIs of adenoviral vectors incorporating GFP (CMV promoter) or NIS (CMV, hTR promoters), vigorously washed Fig. 3 . A, HCT116 cells were infected with Ad-hTR-NIS at MOI 0.01, 0.1, 1, and 10 and irradiated (0, 4, or 8 Gy) 24 h later. Radioiodide uptake assay was done at 72 h, and data were expressed as relative uptake using the 0 Gy data for reference (1.0). Relative iodide uptake was significantly increased at MOI 0.01after both 4 Gy (2.07 F 0.46; P = 0.043) and 8 Gy (2.64 F 0.08; P = 0.002), and at MOI 0.1after both 4 Gy (1.70 F 0.04; P = 0.034) and 8 Gy (2.18 F 0.44; P = 0.025). Relative radioiodide uptake was reduced in the control cells after both 4 Gy (0.69 F 0.15; P = 0.048) and 8 Gy (0.59 F 0.08; P = 0.014), and in cells infected with Ad-hTR-NIS at MOI 10 after 8 Gy (0.62 F 0.04; P = 0.028). Data are representative of at least three repeat experiments. B, data for Ad-hTERT-NIS^infected HCT116 cells. Relative iodide uptake was significantly increased at MOI 1after 4 Gy (1.59 F 0.27; P = 0.025) and 8 Gy (1.76 F 0.13; P = 0.002). Relative radioiodide uptake was reduced in cells infected with Ad-hTERT-NIS at MOI 0.01after 4 Gy (0.56 F 0.16; P = 0.032). Data are representative of at least three repeat experiments. C and D, HCT116 cells were infected with Ad-CMV-GFP (MOI 1) at 0, 24, and 48 h after irradiation (0, 4, or 8 Gy), and GFP expression was measured at 72 h by fluorescence-activated cell sorting analysis. Up-regulation of GFP expression was greatest at 24 h after radiation as shown by the GFP histograms (C) and relative mean fluorescent intensity plots (D). Data are representative of at least three repeat experiments. Research.
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Radiation up-regulates and maintains gene expression from adenoviral vectors in vivo. The effect of EBRT on adenovirusmediated gene expression in vivo was subsequently assessed using GFP-and Luc-expressing vectors. HCT116 tumor-bearing mice received single fraction doses of radiation (0 or 8 Gy) and were injected with Ad-CMV-GFP 24 hours later. GFP expression was analyzed after tumor disaggregation in to a single-cell suspension. GFP expression was increased in irradiated tumors that were injected with Ad-CMV-GFP ( Supplementary Fig. S4 ). The requirement to sacrifice animals to study gene expression resulted in our switching to a noninvasive means of studying gene expression.
Subsequent IVIS camera studies permitted sequential imaging of irradiated and unirradiated tumors in two tumor cell lines (Figs. 5 and 6 ). EBRT was associated with increased total photon flux and maintenance of Luc expression for up to 192 hours (Figs. 5A and 6A ). Mean Luc expression levels were statistically significantly higher for mice treated with virus and EBRT for both HCT116 (Table 1 ; Fig. 5A and B) and H1299 (Table 2 ; Fig. 6A and B) tumors. There was a striking effect of , and radioiodide uptake was measured at 48, 72, 96, and 144 h. After infection at MOI 0.01, radioiodide uptake was significantly increased at 96 h (P = 0.002) after 4 Gy and at 72 h (P = 0.022), 96 h (P = 0.006), and 144 h (P = 0.007) after 8 Gy. After infection at MOI 0.1, radioiodide uptake was significantly increased at 96 h (P = 0.007) after 4 Gy, and at 48 h (P = 0.028), 72 h (P = 0.027), 96 h (P = 0.001), and 144 h (P = 0.004) after 8 Gy. Data are representative of at least three repeat experiments. C and D, up-regulation of gene expression also occurs when radiotherapy is delivered 24 h after infection. HCT116 cells were infected with Ad-CMV-NIS (C) or Ad-hTR-NIS (D; at MOI 0.01, 0.1, 1, 10), washed vigorously, and irradiated (0, 4, or 8 Gy) after 24 h. Radioiodide uptake was measured 72 h after irradiation. Relative iodide uptake was significantly increased at MOI 0.1after 8 Gy (1.77 F 0.25; P = 0.006), at MOI 1after both 4 Gy (1.97 F 0.08; P = 0.001) and 8 Gy (4.40 F 0.34; P < 0.001), and at MOI 10 after both 4 Gy (1.28 F 0.06; P = 0.006) and 8 Gy (1.80 F 0.06; P < 0.001). Relative iodide uptake was significantly increased at MOI 0.1after both 4 Gy (1.87 F 0.36; P = 0.017) and 8 Gy (1.47 F 0.05; P = 0.005), at MOI 1after both 4 Gy (2.89 F 0.13; P = 0.001) and 8 Gy (2.06 F 0.08; P < 0.001), and at MOI 10 after both 4 Gy (1.93 F 0.03; P = 0.001) and 8 Gy (1.69 F 0.05; P < 0.001). Data are representative of at least three repeat experiments. Research.
on January 6, 2018. © 2008 American Association for Cancer clincancerres.aacrjournals.org Downloaded from EBRT on maintenance of Luc expression in both cell lines in vivo. Thus, both total (Figs. 5B and 6B) and relative (Figs. 5C and 6C) levels of Luc expression were maintained to a statistically significantly greater extent in tumors that had received EBRT to a dose of 8 Gy. These data mirror the findings in the in vitro analyses that showed a trend to maintenance and enhancement of relative gene expression at later time points (Fig. 4A and B) . 
Discussion
These studies confirm the potential of combining adenoviral NIS gene therapy with EBRT as a rational strategy for clinical development in treating malignant disease. EBRT is curative in a range of tumor types (head and neck cancer, uterine cervical cancer, and lung cancer), but in the face of advanced disease, the cure rates that are achievable are limited by dose constraints imposed by the risk of normal tissue toxicity (reviewed in ref. 20) . Physical methods to safely escalate dose delivery by intensity-modulated and image-guided radiotherapy may improve treatment outcomes (21 -23) but will also be limited by normal tissue toxicities. Brachytherapy is an alternative means of delivering highly conformal radiation doses selectively to tumor tissues, but its clinical use is restricted to accessible, superficial, early-stage tumors. NIS-mediated biologically targeted radiotherapy is an excellent choice for combination with EBRT on the basis that it may provide a radiation boost to tumor tissue (equivalent to that achievable by intensitymodulated radiotherapy or image-guided radiotherapy) in a highly conformal pattern (as a form of biological brachytherapy). By combining NIS gene therapy with EBRT, even a relatively small dose from radioiodide uptake may yield a significant increase in tumor control probability (16) .
In addition to the potentially additive (or supra-additive) effect of combined doses from EBRT and radioiodide, we showed that this approach offers the potential for exploiting positive interactions between EBRT and viral gene delivery. EBRT increased expression of NIS (and other reporter genes) in a radiation dose-dependent fashion that was most pronounced at low MOIs. This has important implications for clinical studies, given the low transduction rates that would be anticipated in treating most solid cancers. Therefore, increased transgene expression after irradiation will compensate for the relatively low numbers of cells transduced. Ongoing studies in our laboratory are examining the therapeutic efficacy of combining EBRT with NIS gene delivery and 131 I using both in vitro clonogenic and in vivo growth delay assays.
The choice of therapeutic transgene will be extremely important because EBRT-induced up-regulation of adenoviral gene expression will only improve the therapeutic index if there is a potent bystander effect. In other words, increased expression of a therapeutic gene that only kills the cell in which it is expressed is unlikely to improve therapeutic outcomes. NIS gene therapy is an ideal candidate for this approach because radioiodide-concentrating cancer cells will deliver cytotoxic radiation doses to themselves and to neighboring cells (11 -13) . There is also the potential advantage of exploiting the radiation-induced biological bystander effect to kill untransduced tumor cells (14) . In addition, the dosimetric considerations of radioisotopic therapy show a clear relationship between radiation dose delivered and cell kill (24) . Therefore, greater radioiodide uptake will cause higher absorbed doses in the tumor.
The effect of the schedule of EBRT relative to viral infection is complex. When EBRT precedes viral infection, gene expression is highest when the interval between the treatments is 24 hours. This finding mirrors the effect of EBRT on CAR and integrin a v expression and supports the hypothesis that there is enhanced tumor cell transduction. When the schedule is reversed (virus infection precedes EBRT), there is still significant enhancement of gene expression. This finding suggests a posttransductional effect of EBRT on viral gene expression. In addition to the effect on magnitude, EBRT affected duration of gene expression. Thus, radioiodide uptake increased progressively over 6 days after infection of irradiated tumor cells with Ad-hTR-NIS. This finding contrasted sharply with the progressive decline in unirradiated tumor cells. Because therapeutic efficacy is linked to the area under the curve of exposure to h-particles, it is likely that adenoviral delivery of NIS during EBRT will increase the treatment effect. Multiple cooperating factors are likely to increase radioisotope uptake, including increased tumor cell infection, higher peak levels of NIS expression, and maintenance of gene expression over a prolonged period.
It is important to acknowledge that the experiments presented here only provide information on single fraction irradiation delivered predominantly at relatively high doses (4 and 8 Gy). We chose to restrict our initial work in this area to such parameters to enable us to derive a workable experimental model. In fractionated irradiation, cells will be exposed to radiation treatment both before and after viral infection. Therefore, it is reasonable to suppose that results obtained during studies of fractionated courses of EBRT may be somewhat different. We used radiation doses of 4 or 8 Gy to ensure that the single doses that we used would activate changes that were appreciable in the context of in vitro and in vivo experiments. These doses are used in the clinic for symptomatic relief in patients with incurable disease (25 -27) and may well represent a reasonable model in which early clinical evaluation of these effects will be conducted. However, further studies in our laboratory are focusing on fractionated therapy using lower doses per fraction.
EBRT increased adenovirus-mediated viral gene expression from constitutive viral and telomerase promoters, suggesting that the effect was not dependent on the promoter driving the transgene. This has important implications for future clinical applications because it offers the opportunity of exploiting this effect with viral vectors that express therapeutic transgenes from tumor-or tissue-specific promoters and, thus, selectively enhancing radioiodide uptake in cancer cells by means of delivery of EBRT. The relative effects of EBRT on Ad-hTR-NISor Ad-hTERT-NIS -mediated radioiodide uptake in tumor and normal tissues will need to be assessed in careful biodistribution studies before proceeding to clinical evaluation.
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